[HTML][HTML] Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

…, G Scambia, A Lortholary, F Marmé… - … England Journal of …, 2019 - Mass Medical Soc
Background Olaparib has shown significant clinical benefit as maintenance therapy in
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …

Large-scale genotyping identifies 41 new loci associated with breast cancer risk

…, T Truong, P Laurent-Puig, F Menegaux, F Marme… - Nature …, 2013 - nature.com
Breast cancer is the most common cancer among women. Common variants at 27 loci have
been identified as associated with susceptibility to breast cancer, and these account for ∼9…

Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the penelope-B trial

S Loibl, F Marmé, M Martin, M Untch… - Journal of clinical …, 2021 - ingentaconnect.com
PURPOSE About one third of patients with hormone receptor–positive, human epidermal
growth factor receptor 2–negative breast cancer who have residual invasive disease after …

68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer

…, H Winter, PK Plinkert, F Marme… - Journal of Nuclear …, 2019 - Soc Nuclear Med
The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein
inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is …

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

…, T Höfner, M Sprick, M Scharpff, F Marmé… - Nature …, 2013 - nature.com
It has been hypothesized that carcinoma metastasis is initiated by a subpopulation of
circulating tumor cells (CTCs) found in the blood of patients. However, although the presence of …

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

…, C Solbach, J Huober, K Rhiem, F Marmé… - The Lancet …, 2021 - thelancet.com
Background The development of anti-HER2 antibody–drug conjugates opens new therapeutic
options for patients with breast cancer, including patients with low expression of HER2. …

Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

…, C Mulot, M Sanchez, B Burwinkel, F Marme… - Nature …, 2015 - nature.com
Genome-wide association studies (GWAS) and large-scale replication studies have identified
common variants in 79 loci associated with breast cancer, explaining ∼14% of the familial …

Prediction of breast cancer risk based on profiling with common genetic variants

…, MW Beckmann, B Burwinkel, F Marme… - Journal of the …, 2015 - academic.oup.com
Background: Data for multiple common susceptibility alleles for breast cancer may be combined
to identify women at different levels of breast cancer risk. Such stratification could guide …

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

…, JJ Garcia, A Cox, V Shridhar, B Burwinkel, F Marme… - Nature …, 2013 - nature.com
TERT-locus SNPs and leukocyte telomere measures are reportedly associated with risks of
multiple cancers. Using the Illumina custom genotyping array iCOGs, we analyzed ∼480 …

Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes

S Keller, AK König, F Marmé, S Runz, S Wolterink… - Cancer letters, 2009 - Elsevier
Exosomes are membrane vesicles that are released from many different cell types. Tumor
derived-exosomes play a role in immune suppression. We hypothesized that in ovarian …